Bank of America Cites Zoetis Inc.’s (ZTS) Strong Q4 Performance and Fiscal 2026 Outlook

Group 1 - Zoetis Inc. is identified as one of the cheap pharmaceutical stocks to buy according to hedge funds [1] - Bank of America raised its price target for Zoetis to $140 from $135 while maintaining a Neutral rating, supported by the company's fiscal 2026 projections and fourth-quarter performance [2] - The company reported an adjusted EPS of $1.48 for Q4 2025, exceeding the consensus forecast of $1.40, with sales increasing by 3% year-over-year to $2.4 billion [3] Group 2 - For fiscal year 2026, Zoetis projects revenue between $9.83 billion and $10.03 billion and adjusted EPS of $7.00 to $7.10, surpassing analyst forecasts [4] - The expected growth is driven by global operational gains, advancements in parasiticide and dermatology portfolios, and ongoing momentum in companion animal and cattle products [4] - Zoetis is a global leader in animal health, focusing on medicines, vaccines, and diagnostic products for livestock and companion animals [5]